Clinical Trial Update: LDE225 for Patients With PTCH1 or SMO Mutated Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study of LDE225 (sonidegib) for PTCH1- or SMO-activated solid and hematologic tumors was terminated; results were posted on 2016-05-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ptch1- or Smo-activated Hematologic Tumors
• Ptch1- or Smo-activated Solid Tumors

Drugs mentioned

• LDE225 (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PTCH1 or SMO Activated Solid and Hematologic Tumors | Phase 2 | Status: TERMINATED | Results posted: 2016-05-02